Women with advanced breast cancer who progress on prior CDK4/6 inhibition can still benefit from second-line treatment with a CDK4/6 inhibitor as part of combination therapy.

The potential of computational chemistry to revolutionise cancer treatment in Nigeria represents a paradigm shift in medical ...

The antibody-drug conjugate is approved for previously treated advanced NSCLC patients with high c-Met protein overexpression ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 ...

Randee’s cancer had metastasized. When her doctor tested her for the PIK3CA gene mutation, she was able to make informed ...

In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a ...

CytomX Therapeutics, Inc.’s CTMX share price has dipped by 9.45%, which has investors questioning if this is right time to ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

A low-FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, polyols) diet can improve patients' irritable ...

Viridian Therapeutics, Inc.’s VRDN share price has dipped by 5.15%, which has investors questioning if this is right time to ...

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet ...